Antigens Cell-Independent Or T Cell-Dependent Induced Early In

Total Page:16

File Type:pdf, Size:1020Kb

Antigens Cell-Independent Or T Cell-Dependent Induced Early In Long-Lived Bone Marrow Plasma Cells Are Induced Early in Response to T Cell-Independent or T Cell-Dependent Antigens This information is current as of October 2, 2021. Alexandra Bortnick, Irene Chernova, William J. Quinn III, Monica Mugnier, Michael P. Cancro and David Allman J Immunol 2012; 188:5389-5396; Prepublished online 23 April 2012; doi: 10.4049/jimmunol.1102808 Downloaded from http://www.jimmunol.org/content/188/11/5389 Supplementary http://www.jimmunol.org/content/suppl/2012/04/24/jimmunol.110280 Material 8.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/188/11/5389.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 2, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Long-Lived Bone Marrow Plasma Cells Are Induced Early in Response to T Cell-Independent or T Cell-Dependent Antigens Alexandra Bortnick,* Irene Chernova,* William J. Quinn, III,* Monica Mugnier,† Michael P. Cancro,* and David Allman* The signals required to generate long-lived plasma cells remain unresolved. One widely cited model posits that long-lived plasma cells derive from germinal centers (GCs) in response to T cell-dependent (TD) Ags. Thus, T cell-independent (TI) Ags, which fail to sustain GCs, are considered ineffective at generating long-lived plasma cells. However, we show that long-lived hapten-specific plasma cells are readily induced without formation of GCs. Long-lived plasma cells developed in T cell-deficient mice after a single immunization with haptenated LPS, a widely used TI Ag. Long-lived plasma cells also formed in response to TD Ag when the GC response was experimentally prevented. These observations establish that long-lived plasma cells are induced in both TI and TD Downloaded from responses, and can arise independently of B cell maturation in GCs. The Journal of Immunology, 2012, 188: 5389–5396. ntibodies play pivotal roles in host defense and can cause and therefore more protective, Abs (12). This viewpoint is sup- disease when specific for self-antigens. Plasma cells, the ported by data showing that the bulk of BM plasma cells induced main source of Abs, are thought to consist of two pools: by TD Ag secrete high-affinity class-switched Abs (13). However, A http://www.jimmunol.org/ short-lived cells that secrete low-affinity IgM Abs and form extra- the notion that long-lived plasma cells must derive from GCs follicular foci in the spleen or lymph node; and long-lived cells appears incompatible with recent data showing that low-affinity that secrete high-affinity, isotype-switched Abs found mainly in IgM Abs can mediate long-term protection against certain mi- the bone marrow (BM) (1). Whereas short-lived plasma cells die crobial pathogens (14). within 3–5 d (2), long-lived plasma cells are thought to persist for Classically, Ags that do not engage Th cells are thought to months or years in mice and perhaps decades in people (3–6). generate transient IgM responses that reflect the activity of short- Sustained serum Ab titers due to long-lived plasma cells are es- lived plasma cells (2, 15–17). These T cell-independent (TI) Ags sential for protective immunity against many pathogens (3, 7–9). may also generate short-lived GCs that fail to engender SHM Therefore, defining the events underlying the generation of long- and affinity maturation (18, 19). However, several recent studies by guest on October 2, 2021 lived plasma cells is essential for understanding how Ab-mediated challenge the long-standing paradigm that TI Ab responses are immunity is established and maintained. always short-lived. For instance, immunization of T cell-deficient Why some plasma cells achieve longevity whereas others are mice with the spirochete Borrelia hermsii induces long-term IgM- short-lived is not known. One current and widely cited model posits dependent protection (20, 21). IgM Abs induced by the intracel- that long-lived plasma cells emanate chiefly from germinal centers lular bacteria Franciscella tularensis and Ehrlichia muris also (GCs) in response to T cell-dependent (TD) Ags (4, 10). GCs are mediate long-term protection; however, these responses may re- microanatomical structures enriched with Ag-stimulated B cells flect the continuous generation of short-lived Ab-secreting cells undergoing class switch recombination, somatic hypermutation (22, 23). More recently, E. muris and the encapsulated bacterium (SHM), and affinity-based selection (11). Indeed, it was proposed Streptococcus pneumoniae were shown to elicit a long-standing recently that long-lived plasma cells are generated preferentially pool of Ag-specific BM plasma cells in T cell-sufficient mice (24– within the GC to favor the continuous secretion of high-affinity, 26). Although the latter work provides evidence that typical TD Ags are not unique in their ability to induce long-term Ab re- sponses, these studies did not address whether long-lived plasma *Department of Pathology and Laboratory Medicine, University of Pennsylvania cells can be generated in the absence of T cells. Therefore, School of Medicine, Philadelphia, PA 19104; and †Laboratory of Lymphocyte Biol- ogy, The Rockefeller University, New York, NY 10065 whether T cell-derived signals are strictly required to generate Received for publication September 28, 2011. Accepted for publication March 22, long-lived plasma cells remains unclear. 2012. Our work addresses the capacity of TI and TD Ags to induce This work was supported by National Institutes of Health Grants T32 AI070099 (to long-lived plasma cells during the earliest phases of plasma cell A.B.) and R21 AI090700 (to D.A.) and Department of Defense Grant W81WWXWH- differentiation. We show that haptenated LPS, a classic type 1 TI 10-1-0185 (to M.P.C.). Ag, readily induces a long-standing pool of BM plasma cells in Address correspondence and reprint requests to Dr. David Allman, University of mice that lack T cells. These Ab-secreting cells are detected for Pennsylvania, 36th & Hamilton Walk, 230 John Morgan Building, Philadelphia, PA 19104-6082. E-mail address: [email protected] .100 d after a single immunization, exhibit a t1/2 of 45–55 d, and The online version of this article contains supplemental material. arise despite an inability to detect Ag-induced GC B cells. These Abbreviations used in this article: BCL6, B cell lymphoma gene-6; BM, bone mar- data challenge the long-standing notion that type 1 TI Ags fail to row; CGG, chicken g-globulin; GC, germinal center; IR, ionizing radiation; NP, (4- induce the formation of long-lived plasma cells, and suggest that hydroxy-3-nitrophenyl)acetyl; SHM, somatic hypermutation; TD, T cell-dependent; long-lived plasma cells need not arise from GCs. Similarly, we TI, T cell-independent. show that long-lived plasma cells also form in response to a Copyright Ó 2012 by The American Association of Immunologists, Inc. 0022-1767/12/$16.00 standard TD Ag without undergoing maturation and selection in www.jimmunol.org/cgi/doi/10.4049/jimmunol.1102808 5390 LONG-LIVED PLASMA CELLS GCs, as plasma cells secreting low-affinity IgM Abs persisted for Statistical analysis $100 d in mice in which we prevented GC formation early in Significant differences in plasma cell frequencies between two experimen- these responses. These findings indicate that maturation in GCs is tal groups were evaluated with the unpaired two-tailed t test, using Excel not requisite for achieving longevity in the plasma cell lineage and software. also suggest that competence to enter long-lived plasma cell pools is achieved early in TI and TD Ab responses. Results Persistence of LPS-induced TI plasma cells Materials and Methods 2 2 2 2 We immunized C57BL/6 (B6) or T cell-deficient B6.TcRb / d / Mice adults with the hapten (4-hydroxy-3-nitrophenyl)acetyl (NP) con- 2 2 2 2 C57BL/6 (B6), B6.TcRb / d / , and MD4 Ig transgenic (anti-HEL) jugated to LPS or CGG. We studied the Ab response to NP in B6 females (age 8–10 wk) were obtained from Jackson Laboratories. 2 2 background mice for two reasons. First, the kinetics of both AID / mice were provided by Dr. Nina Papavasiliou (The Rockefeller University). All animal procedures were approved by the University of plasma cell differentiation and GC-dependent somatic hypermu- Pennsylvania Office of Regulatory Affairs. tation and selection in response to NP are well established (29, 30). Second, NP-responsive B-lineage cells are readily identified Chimeras by flow cytometry with NP-conjugated fluorescent proteins, and Hosts were exposed to whole-body radiation (900 R) 5 d post immunization, such cells can be resolved in conventional inbred mice without 6 and then given 1 3 10 BM cells i.v. from MD4 IgH+L transgenic mice in using Ig transgenes to increase frequencies of Ag-responsive which all B cells are specific for hen egg lysozyme (27). BM cells were depleted of CD3ε+ cells using a MACs LD column before i.v.
Recommended publications
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Faster Growth with Shorter Antigens Explains a VSG Hierarchy During African Trypanosome Infections: a Feint Attack by Parasites
    bioRxiv preprint doi: https://doi.org/10.1101/131029; this version posted April 26, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Faster growth with shorter antigens explains a VSG hierarchy during African trypanosome infections: a feint attack by parasites Dianbo Liu1, Luca Albergante1,2, David Horn1,*, Timothy Newman1,* 1School of Life Sciences, University of Dundee, Dundee, UK 2U900, Institut Curie, 75005, France *These authors contributed equally Correspondence to [email protected] and [email protected] Abstract The parasitic African trypanosome, Trypanosoma brucei, evades the adaptive host immune response by a process of antigenic variation that involves the clonal switching of variant surface glycoproteins (VSGs). The VSGs that periodically come to dominate in vivo display a hierarchy, but how this hierarchy arises is not well-understood. Combining publicly available genetic data with mathematical modelling, we report a VSG-length-dependent hierarchical timing of clonal VSG dominance in a mouse model, revealing an inverse correlation between VSG length and trypanosome growth-rate. Our analysis indicates that, among parasites switching to new VSGs, those expressing shorter VSGs preferentially accumulate to a detectable level that is sufficient to trigger an effective immune response. Subsequent elimination of faster-growing parasites then allows slower parasites with longer VSGs to accumulate. This interaction between the host and parasite is able by itself to explain the temporal distribution of VSGs observed in vivo.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Plasma Cells: Finding New Light at the End of B Cell Development Kathryn L
    © 2001 Nature Publishing Group http://immunol.nature.com REVIEW Plasma cells: finding new light at the end of B cell development Kathryn L. Calame Plasma cells are cellular factories devoted entire- Upon plasma cell differentiation, there is a marked increase in ly to the manufacture and export of a single prod- steady-state amounts of Ig heavy and light chain mRNA and, when 2 uct: soluble immunoglobulin (Ig). As the final required for IgM and IgA secretion, J chain mRNA . Whether the increase in Ig mRNA is due to increased transcription, increased mediators of a humoral response, plasma cells mRNA stability or, as seems likely, both mechanisms, remains con- play a critical role in adaptive immunity.Although troversial2. There is also an increase in secreted versus membrane intense effort has been devoted to studying the forms of heavy chain mRNA, as determined by differential use of poly(A) sites that may involve the availability of one component of regulation and requirements for early B cell the polyadenylation machinery, cleavage-stimulation factor Cst-643. development, little information has been avail- To accommodate translation and secretion of the abundant Ig able on plasma cells. However, more recent mRNAs, plasma cells have an increased cytoplasmic to nuclear ratio work—including studies on genetically altered and prominent amounts of rough endoplasmic reticulum and secreto- ry vacuoles. mice and data from microarray analyses—has Numerous B cell–specific surface proteins are down-regulated begun to identify the regulatory cascades that upon plasma cell differentiation, including major histocompatibility initiate and maintain the plasma cell phenotype. complex (MHC) class II, B220, CD19, CD21 and CD22.
    [Show full text]
  • REVIEW Multiple Myeloma: the Cells of Origin – a Two-Way Street
    Leukemia (1998) 12, 121–127 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 REVIEW Multiple myeloma: the cells of origin – A two-way street JR Berenson, RA Vescio and J Said West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA, USA Multiple myeloma results from an interplay between the mono- earlier precursor cells may be responsible for the proliferation clonal malignant plasma cells and supporting nonmalignant of the malignant population. The presence of a circulating cells in the bone marrow. Recent studies suggest that the final transforming event in this B cell disorder occurs at a late stage tumor component without obvious plasma cell morphology of B cell differentiation based on the characteristics of the also suggests that less mature lymphocytes may be part of the immunoglobulin genes expressed by the malignant clone as clone as well, which could explain the dissemination of the well as surface markers present on the tumor cells. Recently, disease throughout the bone marrow.4 In addition, evidence an increasing pathogenic role in this malignancy by the nonma- for tumor cells at even earlier stages of hematopoietic differen- lignant cells in the bone marrow has been suggested by several tiation came from studies showing the high rate of acute non- studies. Specific infection of these supporting cells by the lymphoblastic leukemia in these patients and the presence of recently identified Kaposi’s sarcoma-associated herpes virus 5,6 (KSHV) suggests a novel mechanism by which this nonmalig- non-lymphoid surface markers on malignant plasma cells. A nant population may lead to the development of this B cell variety of molecular biological techniques have subsequently malignancy and support its growth.
    [Show full text]
  • Regulatory T Cell Research
    Regulatory T cell research Unique kits for cell isolation Harmonized cell culture and expansion tools Convenient functional assay tools Germany/Austria/ Benelux France Nordics and Baltics South Korea Switzerland Miltenyi Biotec B.V. Miltenyi Biotec SAS Miltenyi Biotec Norden AB Miltenyi Biotec Korea Co., Ltd Reliable flow cytometry analysis Miltenyi Biotec GmbH Schipholweg 68 H 10 rue Mercoeur Scheelevägen 17 Arigi Bldg. 8F Friedrich-Ebert-Straße 68 2316 XE Leiden 75011 Paris, France 223 70 Lund 562 Nonhyeon-ro 51429 Bergisch Gladbach The Netherlands Phone +33 1 56 98 16 16 Sweden Gangnam-gu Germany [email protected] Fax +33 1 56 98 16 17 [email protected] Seoul 06136, South Korea Phone +49 2204 8306-0 Customer service [email protected] Customer service Sweden Phone +82 2 555 1988 Fax +49 2204 85197 The Netherlands Phone 0200-111 800 Fax +82 2 555 8890 [email protected] Phone 0800 4020120 Italy Fax 046-280 72 99 [email protected] Fax 0800 4020100 Miltenyi Biotec S.r.l. Customer service Denmark USA/Canada Customer service Belgium Via Persicetana, 2/D Phone 80 20 30 10 Spain Miltenyi Biotec Inc. Phone 0800 94016 40012 Calderara di Reno (BO) Fax +46 46 280 72 99 Miltenyi Biotec S.L. 2303 Lindbergh Street Fax 0800 99626 Italy Customer service C/Luis Buñuel 2 Auburn, CA 95602, USA Customer service Luxembourg Phone +39 051 6 460 411 Norway, Finland, Iceland, Ciudad de la Imagen Phone 800 FOR MACS Phone 800 24971 Fax +39 051 6 460 499 and Baltic countries 28223 Pozuelo de Alarcón (Madrid) Phone +1 530 888 8871 Fax 800 24984 [email protected] Phone +46 46 280 72 80 Spain Fax +1 877 591 1060 Fax +46 46 280 72 99 Phone +34 91 512 12 90 [email protected] China Japan Fax +34 91 512 12 91 Miltenyi Biotec Technology & Miltenyi Biotec K.K.
    [Show full text]
  • Analysis of Activation Induced Cytidine Deaminase Using Atomic Force Microscopy by C David J
    Analysis of Activation Induced Cytidine Deaminase using Atomic Force Microscopy by c David J. G. Gale A dissertation submitted to the School of Graduate Studies in partial fulfillment of the requirements for the degree of Master of Science Department of Chemistry Memorial University of Newfoundland April 2021 St. John’s Newfoundland Abstract Activation induced cytidine deaminase (AID) plays a large part within the pathway of immunoresponse. It does so by inserting mutations, during DNA replication, in B cells (immune system cells). This results in a more diverse set of antibodies in each subsequent generation. However, mutations that cause infinite replication with no cellular apoptosis, can lead to cancer. AID has been implicated in cancers which appear independent of the expected environmental causes, such as smoking or UV exposure. The method for AID mutations involves binding to single-strand DNA. Using Atomic Force Microscopy (AFM) we obtained both the geometry or topology, as well as the nanomechanical information about this mutation process and AID. In this thesis, I present the first AFM images of AID, showing direct structural information about the protein. Although the measurements are done in vitro, physiological con- ditions have been approximated in order to get an accurate analysis of the protein system. To allow imaging in buffer, suitable substrates were tested and identified which would bind the protein sufficiently in this high ionic strength environment. Optimized plating and scan conditions for AID in both wet and dry conditions are described, which allow high resolution imaging to be performed that is not often seen in biological systems. Through the many scans and procedural changes it was estab- lished that although difficult it is possible to gain an image of AID through the use ii of AFM.
    [Show full text]
  • Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Research Information System University of Turin Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs Gianfranco Pittari1, Luca Vago2,3, Moreno Festuccia4,5, Chiara Bonini6,7, Deena Mudawi1, Luisa Giaccone4,5 and Benedetto Bruno4,5* 1 Department of Medical Oncology, National Center for Cancer Care and Research, HMC, Doha, Qatar, 2 Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy, 3 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 4 Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy, 5 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, 6 Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy, 7 Vita-Salute San Raffaele University, Milano, Italy Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediated killing via engagement of tumor ligands for NK activating receptors or “missing-self” recognition. Similar to other cancers, MM targets may elude NK cell immunosurveillance by reprogramming tumor microenvironment and editing cell surface antigen repertoire. Along disease continuum, these effects collectively result in a pro- gressive decline of NK cell immunity, a phenomenon increasingly recognized as a critical determinant of MM progression. In recent years, unprecedented efforts in drug devel- opment and experimental research have brought about emergence of novel therapeutic interventions with the potential to override MM-induced NK cell immunosuppression.
    [Show full text]
  • The Anatomy of T-Cell Activation and Tolerance Anna Mondino*T, Alexander Khoruts*, and Marc K
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 2245-2252, March 1996 Review The anatomy of T-cell activation and tolerance Anna Mondino*t, Alexander Khoruts*, and Marc K. Jenkins Department of Microbiology and the Center for Immunology, University of Minnesota Medical School, 420 Delaware Street S.E, Minneapolis, MN 55455 ABSTRACT The mammalian im- In recent years, it has become clear that TCR is specific for a self peptide-class I mune system must specifically recognize a full understanding of immune tolerance MHC complex) T cell that will exit the and eliminate foreign invaders but refrain cannot be achieved with reductionist in thymus and seed the secondary lymphoid from damaging the host. This task is vitro approaches that separate the individ- tissues (3, 4). In contrast, cortical CD4+ accomplished in part by the production of ual lymphocyte from its in vivo environ- CD8+ thymocytes that express TCRs that a large number of T lymphocytes, each ment. The in vivo immune response is a have no avidity for self peptide-MHC bearing a different antigen receptor to well-organized process that involves mul- complexes do not survive and die by an match the enormous variety of antigens tiple interactions of lymphocytes with each apoptotic mechanism. Cortical epithelial present in the microbial world. However, other, with bone-marrow-derived antigen- cells are essential for the process of pos- because antigen receptor diversity is gen- presenting cells (APCs), as well as with itive selection because they display the self erated by a random mechanism, the im- nonlymphoid cells and their products. The peptide-MHC complexes that are recog- mune system must tolerate the function of anatomic features that are designed to op- nized by CD4+ CD8+ thymocytes and also T lymphocytes that by chance express a timize immune tolerance toward innocuous provide essential differentiation factors self-reactive antigen receptor.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]